Adenomatous Polyposis Coli loss controls cell cycle regulators and response to paclitaxel in MDA-MB-157 metaplastic breast cancer cells

Adenomatous Polyposis Coli loss controls cell cycle regulators and response to paclitaxel in MDA-MB-157 metaplastic breast cancer cells

Show other versions (1)

Adenomatous Polyposis Coli (APC) is lost in approximately 70% of sporadic breast cancers, with an inclination towards triple negative breast cancer (TNBC). TNBC is treated with traditional chemotherapy, such as paclitaxel (PTX); however, tumors often develop drug resistance. We previously created AP...

Full description

Bibliographic Details
Main Authors: Emily M. Astarita, Sara M. Maloney, Camden A. Hoover, Bronwyn J. Berkeley, Monica K. VanKlompenberg, T. Murlidharan Nair, Jenifer R. Prosperi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351968/?tool=EBI

Similar Items

Similar Items